Open AccessPrognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy
Author(s) -
Kang Min Kyu,
Lee Shin Yup,
Choi Jin Eun,
Baek Sun Ah,
Do Sook Kyung,
Lee Jeong Eun,
Park Jongmoo,
Yoo Seung Soo,
Choi Sunha,
Shin Kyung Min,
Jeong Ji Yun,
Park Jae Yong
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13851
Subject(s) - medicine , single nucleotide polymorphism , hazard ratio , lung cancer , oncology , chemoradiotherapy , stage (stratigraphy) , haplotype , radiation therapy , gastroenterology , linkage disequilibrium , confidence interval , proportional hazards model , allele , genotype , gene , genetics , biology , paleontology
Background To examine the impact of polymorphisms of glucose transporter 1 ( GLUT1 ) gene on the prognosis of patients with stage III non‐small cell lung cancer (NSCLC) who received radiotherapy. Methods Five single nucleotide polymorphisms (SNPs) (rs4658C>G, rs1385129G>A, rs3820589A>T, rs3806401A>C and rs3806400C>T) in GLUT1 gene were evaluated in 90 patients with pathologically confirmed stage III NSCLC. A total of 21 patients were treated with radiotherapy alone, 25 with sequential chemoradiotherapy, and 44 with concurrent chemoradiotherapy. The association of the genetic variations of five SNPs with overall survival (OS) and progression‐free survival (PFS) was analyzed. Results Two SNPs (rs1385129 and rs3806401) were significant risk factors for OS. Three SNPs (rs1385129, rs3820589 and rs3806401) were in linkage disequilibrium. In Cox proportional hazard models, GAA haplotype was a good prognostic factor for OS (hazard ratio [HR] = 0.57, 95% confidence interval [CI]: 0.39–0.81, p = 0.002) and PFS (HR = 0.68, 95% CI: 0.47–0.99, p = 0.043), compared to variant haplotypes. The GAA/GAA diplotype was observed in 46.7% of patients; these patients showed significantly better OS (HR = 0.38, 95% CI: 0.22–0.65, p < 0.001) and PFS (HR = 0.51, 95% CI: 0.31–0.85, p = 0.009) compared to those with other diplotypes. Conclusions These results suggest that polymorphisms of GLUT1 gene could be used as a prognostic marker for patients with stage III NSCLC treated with radiotherapy.